Please login to the form below
Orencia
This page shows the latest Orencia news and features for those working in and with pharma, biotech and healthcare.
BMS’ Opdivo stalls in Q3, but overall figures still top expectations
Anticoagulant Eliquis (apixaban) did better than predicted with a 22% increase to $1.93bn, and there were also solid gains for arthritis and psoriasis therapy Orencia (abatacept) – up 14% to $767m –
Latest news
-
Pfizer closes on EU approval of lung cancer drug Vizimpro
Bristol-Myers Squibb’s Orencia (abatacept) was backed as a second-line treatment for moderate to severe active polyarticular juvenile idiopathic arthritis (pJIA) in paediatric patients (2 years and older), and
-
Opdivo drives growth at BMS, but US sales slow down
Overall, BMS reported fourth-quarter revenues up 22% to $5.2bn, with a solid showing from novel oral anticoagulant Eliquis (apixaban), which leaped 57% to $346m and rheumatoid arthritis therapy Orencia
-
Opdivo drives gain in BMS sales, but business revamp coming
Away from cancer, rheumatoid arthritis treatment Orencia (abatacept) continued its buoyant run with an 18% increase to $572m, while novel oral anticoagulant Eliquis (apixaban) brought in $884m, a rise of 90%.
-
Shire gives up on Momenta-partnered Humira biosimilar
It also has a biosimilar collaboration with generics giant Mylan covering six biologics, headed by M834, a biosimilar version of Bristol-Myers Squibb's rheumatoid arthritis drug Orencia (abatacept).
-
Mylan buys into six biosimilars, including Orencia candidate
The agreement gives Mylan the rights to six biosimilars in Momenta's pipeline, including a version of Bristol-Myers Squibb's rheumatoid arthritis therapy Orencia (abatacept) which brought in sales of
Pfizer closes on EU approval of lung cancer drug Vizimpro
Opdivo drives growth at BMS, but US sales slow down
Shire gives up on Momenta-partnered Humira biosimilar
Mylan buys into six biosimilars, including Orencia candidate
More from news
Approximately 8 fully matching, plus 29 partially matching documents found.
Latest Intelligence
-
Deal Watch January 2016
255. Mylan/ Momenta. Co-development, co-commercialisation . Exclusive global collaboration with Momenta for 6 biosimilars including a biosimilar version of Orencia (abatacept) . 245. Athersys/ Healios. Licence. Development and commercialisation
-
Biosimilars - the same, but different?
Orencia and Actemra for rheumatoid arthritis.
Deal Watch January 2016
Biosimilars - the same, but different?
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
BMS’ Brian Daniels to retire
Dr Daniels has been with BMS since 2000 as VP of the immunology, pulmonary, and dermatology therapeutic area where he worked on such compounds as rheumatoid arthritis drug Orencia (abatacept).
BMS’ Brian Daniels to retire
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Brand leaders in RA will lose market share, predict rheumatologists
leaders Enbrel (etanercept) and Humira (adalimumab) will continue to lose market share to newer biologics such as RoActemra (tocilizumab), Orencia (abatacept) and Simponi (golimumab) and may experience strong competition from biosimilar
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Management Trainer, Medical Communications, Londo...
-
Highly competitive salary
- Account Director, Medical & Brand Communications, London/ SE...
-
Highly competitive salary
- Editorial Director - UK, , EUROPE, REMOTE.
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director, Medical & Brand Communications, Lon...
-
Highly competitive salary
- Freelance Scientific Director, Medical Communications, London/ S...
-
Highly competitive salary
-
CEO Pricing & Market Access, UK
-
Six figure salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Embattled Biogen talks up Aduhelm
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- David Hunt launches independent agency The Considered
- EU “still interested” in Valneva COVID vaccine despite UK snub
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- FDA’s director and deputy director of its Office of Vaccines Research & Review resign
- New data from Moderna supports COVID boosters
- $47.5m research centre to seek genetic insights into disease
- Havas Life Medicom and ARK lead at 2021 PM Society Digital Awards
- Nicky Hutchens appointed as deputy managing director at Four Health
- Health For All
- Digitalizing Muskuloskeletal Care to Improve Patient Outcomes and Reduce Cost
No results were found
PMHub
Branding Science
We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...
Latest intelligence
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
- Rare thoughts & outcomes - navigating pathways to better outcomes in rare
- ...
- How to pick the perfect training program for your healthcare professionals
- You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...
